retatrutide turkey (LY3437943) | GCGR/GLP-1R/GIPR Agonist | CAS 2381089-83-2 Retatrutide trifluoroacetate | 2381089-83-2 |

doi: 10.1002/acr.20623 19 KwokLWTamLSZhuTLeungYYLiE

Findings to date remain researchfocused

The same group (Coskun et al

The body has fully adapted to the medication while therapeutic benefits continue

Lipid Panel Changes Retatrutide consistently improves lipid profiles: Triglycerides: Significant reductions, driven by reduced hepatic VLDL production and improved fat metabolism LDL cholesterol: Modest reductions observed HDL cholesterol: Tends to be preserved or mildly increased Non-HDL cholesterol: Meaningful improvements across studies These lipid changes are clinically relevant and contribute to the overall cardiovascular risk reduction profile